Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.2K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.2K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

727
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
727
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy01:26

Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy

364
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
364
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

532
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
532
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

284
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

JCO precision oncology·2026
Same author

Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.

Journal of neuroendocrinology·2026
Same author

Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease.

Journal of neuroendocrinology·2026
Same author

Small Cell and Large Cell Neuroendocrine Carcinoma of the Colon and Rectum: Population-Based Analysis of Incidence, Survival, and Site-Specific Outcomes.

Cancers·2026
Same author

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience.

The oncologist·2026

Related Experiment Video

Updated: Jan 13, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K

Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma.

Jack Korleski1, Luis E Ospina Velasquez2, Joshua Bornhorst3

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Endocrine-Related Cancer
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

Diagnosing VIPoma, a rare neuroendocrine tumor, is difficult. This study found that while elevated vasoactive intestinal peptide (VIP) levels can occur, a threshold of 442 pg/mL is optimal for predicting VIPoma, avoiding unnecessary tests.

Keywords:
chronic diarrheadiagnostic accuracy

More Related Videos

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis
04:09

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis

Published on: June 21, 2024

2.6K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K

Related Experiment Videos

Last Updated: Jan 13, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K
Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis
04:09

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis

Published on: June 21, 2024

2.6K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K

Area of Science:

  • Endocrinology
  • Oncology
  • Gastroenterology

Background:

  • VIPoma is a rare neuroendocrine tumor (NET) with diagnostic challenges.
  • Elevated vasoactive intestinal peptide (VIP) levels are characteristic but lack a defined diagnostic threshold.
  • Accurate VIP level interpretation is crucial for diagnosing VIPoma.

Purpose of the Study:

  • To determine the optimal threshold for plasma VIP concentrations in diagnosing VIPoma.
  • To compare VIP levels in patients with and without VIPoma.
  • To evaluate the diagnostic utility of VIP testing in a single institution population.

Main Methods:

  • Retrospective review of VIP test results (2011-2023) for patients with VIP levels > 75 pg/mL.
  • Comparison of plasma VIP concentrations between confirmed VIPoma and non-VIPoma cohorts.
  • Statistical analysis to determine the optimal VIP threshold and its predictive value.

Main Results:

  • Nine VIPomas were diagnosed among 76 eligible patients; all had chronic diarrhea.
  • The mean VIP concentration was higher in VIPoma patients (508 pg/mL) vs. non-VIPoma (223 pg/mL), but not statistically significant (p=0.31).
  • An optimal VIP threshold of 442 pg/mL was identified (OR: 11.96, p=0.01), with significant odds ratios starting at 200 pg/mL. The positive predictive value at 75 pg/mL was only 12%.

Conclusions:

  • Elevated VIP concentrations alone are not highly predictive of VIPoma.
  • Most patients with elevated VIP levels do not have VIPoma.
  • Recommend judicious use of VIP testing in specific clinical scenarios to prevent unnecessary investigations.